This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: University of California. Active years: 2022-2026.
Company Filing History:
Years Active: 2022-2026
Title: Kuo-Ching Mei: Innovator in Nano-Enabled Immunotherapy
Introduction
Kuo-Ching Mei is a prominent inventor based in Los Angeles, CA. He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. With a total of 2 patents, Mei is recognized for his work in developing advanced therapeutic methods.
Latest Patents
One of Kuo-Ching Mei's latest patents is titled "NANO-ENABLED IMMUNOTHERAPY IN CANCER." This patent describes a platform technology designed to facilitate immune therapy in the treatment of cancer. The invention includes nanocarriers that enhance the delivery of an IDO inhibitor alongside an inducer of cell death (ICD-inducer). In specific embodiments, the IDO inhibitor is conjugated to a component of a lipid bilayer, forming a nanovesicle. Additionally, the patent outlines methods and compositions where an ICD-inducing agent, such as doxorubicin or oxaliplatin, is integrated into a nanocarrier, allowing for systemic delivery to orthotopic pancreatic cancer sites.
Career Highlights
Kuo-Ching Mei is affiliated with the University of California, where he continues to advance his research in immunotherapy and nanotechnology. His work has garnered attention for its potential to improve cancer treatment outcomes.
Collaborations
Mei collaborates with esteemed colleagues, including Andre E Nel and Huan Meng, who contribute to his research endeavors and enhance the impact of his innovations.
Conclusion
Kuo-Ching Mei is a leading figure in the field of nano-enabled immunotherapy, with a focus on innovative solutions for cancer treatment. His contributions through patents and collaborations highlight his commitment to advancing medical science.